Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Migal Galilee Research Institute Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are spread across 3 distinct examiners and a corresponding number of distinct art units. MOAZZAMI, NAGHMEH NINA is the busiest examiner for this portfolio.
The distribution of 3 pending office actions among 3 distinct examiners indicates that each action is being evaluated independently. No single examiner or art unit holds more than 1 pending action. This one to one ratio between actions and examiners suggests a broad technical scope within the Biotechnology & Pharmaceuticals area.
Practitioners should be prepared to navigate the specific requirements of multiple distinct art units. With the busiest examiner and two others each holding a single pending office action, the prosecution strategy must be adapted for three different individual perspectives. This decentralized structure requires careful attention to the unique behaviors of each assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOAZZAMI, NAGHMEH NINA | 1 | 72.0% | +49.3% |
| LANGEL, WAYNE A | 1 | 78.4% | +23.2% |
| MOEHLMAN, ANDREW TERRY | 1 | 66.3% | +61.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290897 | QUORUM QUENCHING ENZYME, AND METHODS OF USING SAME | MOAZZAMI, NAGHMEH NINA | 28d |
| 18274060 | FERTILIZER COMPOSITIONS AND METHODS OF USING SAME | LANGEL, WAYNE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290897 | QUORUM QUENCHING ENZYME, AND METHODS OF USING SAME | MOAZZAMI, NAGHMEH NINA | 28d |
| 18274060 | FERTILIZER COMPOSITIONS AND METHODS OF USING SAME | LANGEL, WAYNE A | — |
| 18336378 | LACTONASE AND STABILIZED MUTANTS THEREOF FOR TREATING FUNGAL INFECTIONS IN PLANTS | MOEHLMAN, ANDREW TERRY | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1736 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290897 | QUORUM QUENCHING ENZYME, AND METHODS OF USING SAME | MOAZZAMI, NAGHMEH NINA | 1652 | §101§112 | Non-Final OA | 28d | Pending | Jan 22, 2024 |
| 18274060 | FERTILIZER COMPOSITIONS AND METHODS OF USING SAME | LANGEL, WAYNE A | 1736 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18336378 | LACTONASE AND STABILIZED MUTANTS THEREOF FOR TREATING FUNGAL INFECTIONS IN PLANTS | MOEHLMAN, ANDREW TERRY | 1655 | §103§112DP | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial